Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Aytu Biopharma (AYTU) Short-Term Debt repayments (2021 - 2022)

Aytu Biopharma (AYTU) has disclosed Short-Term Debt repayments for 2 consecutive years, with $30.5 million as the latest value for Q3 2022.

  • On a quarterly basis, Short-Term Debt repayments fell 33.11% to $30.5 million in Q3 2022 year-over-year; TTM through Sep 2022 was $163.5 million, a N/A change, with the full-year FY2022 number at $156.4 million, up 189.66% from a year prior.
  • Short-Term Debt repayments was $30.5 million for Q3 2022 at Aytu Biopharma, down from $39.3 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $48.0 million in Q2 2021 to a low of $30.5 million in Q3 2022.